Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Richter transformation (RT) of chronic lymphocytic leukemia (CLL) presents a significant clinical challenge due to chemoresistance and high mortality.
• Current therapeutic options for RT are limited, necessitating the exploration of novel treatment strategies.
• Cellular immunotherapies, such as chimeric antigen receptor T cells, show promise but face limitations like manufacturing time delays and insufficient effector cell numbers in immunocompromised patients.

Observation:

• Gamma delta (γδ) T cells offer a potential alternative, exhibiting broad antitumor activity and suitability for allogeneic transplantation.
• γδ T cells can be expanded in vivo and their efficacy enhanced by monoclonal antibodies, as suggested by in vitro studies.
• This report details a case of a patient with refractory RT who underwent an individualized treatment combining haploidentical γδ T cell transfer with obinutuzumab.

Findings:

• The patient achieved a histologically confirmed complete remission following the combined therapy.
• No significant adverse side effects were observed during the treatment course.
• This outcome demonstrates the feasibility and potential efficacy of combining γδ T cells with monoclonal antibodies for RT.

Implications:

• This case underscores the therapeutic potential of γδ T cell therapy, particularly in combination with targeted antibodies, for managing refractory Richter transformation.
• The successful outcome suggests that this approach warrants further investigation in clinical trials for patients with advanced CLL transformation.
• This strategy may offer a viable treatment option for patients with limited alternatives, potentially improving survival rates and quality of life.